Tag Archives: mrk

Merck Up On Q1, Januvia Report; Bristol, Pfizer Mixed

Merck (MRK) stock jumped more than 5% Tuesday as the company led a trio of big pharmas reporting first-quarter earnings, bolstered by good news on its diabetes franchise. Merck reported earnings of 85 cents a share, down 3% from the year-earlier quarter but 10 cents better than analysts’ consensus. Sales shrank 8% to $9.43 billion, beating consensus by nearly $400 million. Investors were also in a buoyant mood after Merck announced late Monday

After Hours: Merck Perks; Pot Biotech Is A Downer

Shares of Merck (MRK) rose 3% in after-hours trading after the company announced trial results that show best-selling diabetes treatment Januvia doesn’t increase the risk of stroke and other heart issues in diabetes patients. In adults with type 2 diabetes and a history of heart disease, the study found that the drug didn’t change the “composite of time” to the first occurrence of “cardiovascular-related death, nonfatal myocardial infarction,

Merck HCV Drugs Hit Trial Goals, Win Fast FDA Review

Big pharma Merck (MRK) released late-stage data Wednesday on its hepatitis C regime that met Wall Street’s expectations, and also announced that the FDA had awarded it breakthrough therapy designation for certain patient groups. Merck’s 14 studies were among a passel of newly released abstracts for presentations at the annual meeting of the European Association for the Study of Liver (EASL), convening April 22 to 26 in Vienna. The combination